Other factors that suggest a poorer prognosis include a Preceding myelodysplastic phase Therapy-related AML High WBC count (> about 50, 000 / microL [> 50 × 10 9 / L]) Patient-specific adverse prognostic factors include age ≥ 65, poor performance status, and comorbidities.